D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $25.00 price objective on the stock.

HUMA has been the subject of several other reports. Wall Street Zen cut Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Benchmark cut their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, January 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. UBS Group reaffirmed a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a research note on Monday, December 1st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.14.

Humacyte Trading Down 5.3%

Shares of Humacyte stock opened at $1.08 on Thursday. The firm has a market cap of $202.25 million, a price-to-earnings ratio of -4.70 and a beta of 1.93. Humacyte has a 52-week low of $0.88 and a 52-week high of $3.94. The company’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.41. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97.

Institutional Trading of Humacyte

Several large investors have recently modified their holdings of HUMA. ProShare Advisors LLC raised its position in shares of Humacyte by 24.1% during the 2nd quarter. ProShare Advisors LLC now owns 31,493 shares of the company’s stock worth $66,000 after purchasing an additional 6,106 shares during the last quarter. Beacon Pointe Advisors LLC lifted its position in shares of Humacyte by 28.6% in the second quarter. Beacon Pointe Advisors LLC now owns 36,000 shares of the company’s stock valued at $75,000 after acquiring an additional 8,000 shares in the last quarter. Concurrent Investment Advisors LLC boosted its stake in shares of Humacyte by 16.6% during the third quarter. Concurrent Investment Advisors LLC now owns 59,615 shares of the company’s stock valued at $104,000 after acquiring an additional 8,500 shares during the last quarter. SG Americas Securities LLC increased its position in Humacyte by 50.3% during the 4th quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after purchasing an additional 11,411 shares in the last quarter. Finally, Independent Advisor Alliance raised its stake in Humacyte by 49.4% in the 3rd quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock valued at $63,000 after purchasing an additional 11,991 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.